DeepCure is focused on developing innovative small molecule therapies aimed at treating immune diseases. The company collaborates with leading researchers at the Leeds Institute of Rheumatic and Musculoskeletal Medicine to enhance its research capabilities. One of its notable advancements is the development of DC-9476, a candidate for treating multiple autoimmune diseases, including rheumatoid arthritis. Additionally, DeepCure's Inspired Chemistry™ platform facilitates automated chemical synthesis, enabling the creation of a top-selling drug along with 58 diverse analogs, showcasing the company's commitment to advancing therapeutic options.

In its pipeline, DeepCure is working on several promising candidates targeting various immune-related conditions. The BRD4-BD2 compound is in the IND-Enabling phase for oral administration, aimed at treating rheumatoid arthritis, Still's disease, and hidradenitis suppurativa. Another candidate, STAT6, is also in the IND-Enabling phase and targets asthma and atopic dermatitis. The company is actively pursuing both early and late discovery projects, including an undisclosed target for autoimmune indications, reflecting its strategic focus on addressing a range of immune diseases through small molecule therapeutics.

United States

DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and cheaper way. The company was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. DeepCure does not use AI to simply generate a profile of the target candidate profile (TCP), but instead re-engineers drug discovery to deliver transformative results.

DeepCure

Company Details